GlobeNewsWire
22 Jul 2026, 10:47 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Insulet Corporation faces a securities fraud class action lawsuit alleging it misrepresented the safety of its Omnipod products and concealed manufacturing defects. — Legal proceedings for fraud and safety failures create significant financial risk and potential liability for the company.
-0.60Insulet issued multiple voluntary medical device corrections for Omnipod 5, DASH, and Eros systems due to internal tubing tears that could lead to insulin under-delivery. — Recurring manufacturing defects in core product lines threaten patient safety and erode confidence in product quality.
-0.50The disclosure of these manufacturing issues led to a significant stock price decline, including a drop of 6.88% in March 2026 and a further decline in May 2026. — This confirms the market's negative reaction to the safety issues, establishing a trend of volatility and loss of valuation.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities fraud class action lawsuit following product manufacturing defects and significant stock price drops.
Mentioned only as a past legal success for the law firm, with no current impact on the company's value.
Mentioned only as a past legal success for the law firm, with no current impact on the company's value.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
